Abstract:BACKGROUND: Onychomycosis is one of the commonest dermatological diseases worldwide. The antifungal activity of current medications varies, and treatment failure occurs in 25-40% of treated patients.AIMS: To evaluate the in vitro antifungal activity of itraconazole, fluconazole, terbinafine and voriconazole against isolates taken from patients with onychomycosis.METHODS: Nail isolates were evaluated according to methods described in the protocols of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antimicrobial Susceptibility Testing (AFST-EUCAST) and the Clinical and Laboratory Standards Institute (CLS M38-A), and a CLSI M38-A modified technique for dermatophytes. Antifungal agents tested included terbinafine, itraconazole, voriconazole and fluconazole.RESULTS: In total, 103 isolates of Candida species (n = 58), Fusarium species (n = 10), Fusicoccum dimidiatum (n = 4), Scytalidium hyalinum (n = 1) and dermatophytes (n = 30) were evaluated. Itraconazole and voriconazole were the most active agents against Candida species, whereas terbinafine and voriconazole were most potent against dermatophytes. Fusarium species had the highest minimum inhibitory concentration (MIC) values with all antifungal agents.CONCLUSIONS: The aetiological agents of onychomycosis that we found differ from those found in other countries, suggesting that the heat and humidity of the Colombian climate could favour yeast nail infections. The lowest MICs for Candida species (obtained with voriconazole, followed by itraconazole) may be explained by emerging resistant strains. Against dermatophytes, the lowest MICs were obtained with terbinafine, followed by voriconazole. MIC values for the evaluated agents were higher for non-dermatophyte filamentous fungi than for other fungi. As MIC breakpoints have not yet been established for onychomycosis therapies, it remains unclear if in vitro activities of antifungal drugs are predictive of clinical outcome. Well-designed clinical studies are necessary to assist clinicians in choosing the best antifungal agents.

Evaluation of in Vitro Antifungal Activities of Bifonazole-triamcinolone Acetonide Against Dermatophytes

In Vitro Interaction of Itraconazole with Amphotericin B, Caspofungin, and Terbinafine Against Clinical Isolates of Trichosporon asahii

In Vitro Interactions of Micafungin with Amphotericin B, Itraconazole or Fluconazole Against the Pathogenic Phase of Penicillium Marneffei.

Comparative Evaluation of ATB FUNGUS 3 Procedure and CLSI M27-A2 Broth Microdilution Method for Antifungal Susceptibility Testing of Pathogenic Yeasts

Terbinafine versus itraconazole for treatment of dermatophyte onychomycosis: a meta-analysis

In vitro activities of flutrimazole against fungal pathogens isolated from tinea pedis

Evaluation of in vitro antifungal activities of six antifungal agents against dermatophytes

In Vitro Testing of Amorolfine in Combination with Terbinafine and Itraconazone Against Fungal Isolates in Onychomycosis

In vitro activity of terbinafine in combinations with other antifungi drugs against clinical pathogenic fungi of vulvovaginal candidiasis

In Vitro Antifungal Activity of Caspofungin and Micafungin Against 8 Species of Dermatophyte

In vitro susceptibility testing of the combination of terbinafine and itraconazole against dematiaceous fungi

In vitro activities of nine antifungal agents against rare pathogenic fungi.

Comparison of the in vitro activity of terbinafine and lanoconazole against dermatophytes

Activities of Terbinafine in Combination with Itraconazole and Fluconazole Against Isolates of Candida albicans In Vitro

In Vitro Activities of Nine Antifungal Drugs and Their Combinations against Phialophora verrucosa

Antifungal susceptibility test for pathogenic Fusarium spp in vitro

In vitro determination of the combination of ciclopirox and terbinafine in the treatment of dermatophytosis

In Vitro Antifungal Activity of Tacrolimus Alone or in Combination with Itraconazole or Terbinafine Against Exophiala Dermatitidis

In vitro activities of terbinafine in combination with fluconazole and itraconazole against isolates of Candida albicans with reduced susceptibility to azoles

In vitro activity of fluconazole, itraconazole, voriconazole and terbinafine against fungi causing onychomycosis

In Vitro Activities of Terbinafine against Cutaneous Isolates of Candida albicans and Other Pathogenic Yeasts